VIATRIS INC. Revenue Not from Contract with Customer
VIATRIS INC. (VTRS) reported Revenue Not from Contract with Customer of $10.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RevenueNotFromContractWithCustomer · last filed 2026-08-06
- VIATRIS INC. revenue not from contract with customer for the quarter ending 2026-06-30 was $10.90M, a 16.79% decline year-over-year.
- VIATRIS INC. revenue not from contract with customer for the quarter ending 2026-03-31 was $7.30M, a 34.23% decline year-over-year.
- VIATRIS INC. revenue not from contract with customer for the quarter ending 2025-12-31 was $12.90M, a 1.57% increase year-over-year.
- VIATRIS INC. revenue not from contract with customer for the quarter ending 2025-09-30 was $12.40M, a 6.06% decline year-over-year.
- VIATRIS INC. revenue not from contract with customer for fiscal 2025 was $49.50M, a 6.45% increase from fiscal 2024.
- VIATRIS INC. revenue not from contract with customer for fiscal 2024 was $46.50M, a 20.78% increase from fiscal 2023.
- VIATRIS INC. revenue not from contract with customer for fiscal 2023 was $38.50M, a 13.68% decline from fiscal 2022.
- VIATRIS INC. revenue not from contract with customer for fiscal 2022 was $44.60M.
| Period end | Revenue Not from Contract with Customer 3 month | Revenue Not from Contract with Customer 6 month | Revenue Not from Contract with Customer 9 month | Revenue Not from Contract with Customer 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.90M 10-Q · filed 2026-08-06 | $18.20M 10-Q · filed 2026-08-06 | $31.10M derived: sum of 3 quarters · filed 2026-08-06 | $43.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $7.30M 10-Q · filed 2026-05-07 | $20.20M derived: sum of 2 quarters · filed 2026-05-07 | $32.60M derived: sum of 3 quarters · filed 2026-05-07 | $45.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $12.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.30M derived: sum of 2 quarters · filed 2026-02-26 | $38.40M derived: sum of 3 quarters · filed 2026-08-06 | $49.50M 10-K · filed 2026-02-26 |
| 2025-09-30 | $12.40M 10-Q · filed 2025-11-06 | $25.50M derived: sum of 2 quarters · filed 2026-08-06 | $36.60M 10-Q · filed 2025-11-06 | $49.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $13.10M 10-Q · filed 2026-08-06 | $24.20M 10-Q · filed 2026-08-06 | $36.90M derived: sum of 3 quarters · filed 2026-08-06 | $50.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $11.10M 10-Q · filed 2026-05-07 | $23.80M derived: sum of 2 quarters · filed 2026-05-07 | $37.00M derived: sum of 3 quarters · filed 2026-05-07 | $47.70M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $12.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.90M derived: sum of 2 quarters · filed 2026-02-26 | $36.60M derived: sum of 3 quarters · filed 2026-02-26 | $46.50M 10-K · filed 2026-02-26 |
| 2024-09-30 | $13.20M 10-Q · filed 2025-11-06 | $23.90M derived: sum of 2 quarters · filed 2025-11-06 | $33.80M 10-Q · filed 2025-11-06 | $45.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $10.70M 10-Q · filed 2025-08-07 | $20.60M 10-Q · filed 2025-08-07 | $32.00M derived: sum of 3 quarters · filed 2026-02-26 | $40.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $9.90M 10-Q · filed 2025-05-08 | $21.30M derived: sum of 2 quarters · filed 2026-02-26 | $29.30M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $11.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $19.40M derived: sum of 2 quarters · filed 2026-02-26 | $38.50M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $8.00M 10-Q · filed 2024-11-07 | $27.10M 10-Q · filed 2024-11-07 | ||
| 2022-12-31 | $44.60M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |